Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850298 | 1.00 | TUBB1 (0.42) | TUBB1CA1CA2CA7CYP1A2 | |
| SCHEMBL59877 | 1.00 | TUBB1 (0.42) | TUBB1CA1CA2CA7CYP1A2 | |
| SCHEMBL13660107 | 1.00 | TUBB1 (0.42) | TUBB1CA1CA2CA7CYP1A2 | |
| SCHEMBL59332 | 0.89 | CTSK (0.39) | TUBB1CA1CA2CA7CYP1A2 | |
| SCHEMBL59546 | 0.89 | CTSK (0.39) | TUBB1CA1CA2CA7CYP1A2 | |
| SCHEMBL22315400 | 0.89 | TUBB1 (0.46) | TUBB1CA1CA2CA7CTSK | |
| SCHEMBL58336 | 0.87 | TUBB1 (0.54) | TUBB1CTSKCTSLCTSS | |
| SCHEMBL58210 | 0.86 | TUBB1 (0.43) | TUBB1 | |
| SCHEMBL16869955 | 0.86 | CTSS (0.42) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL6688667 | 0.86 | CA1 (0.36) | CA1CA2CA7CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885CA1 4689/4885CA2 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.